Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 6/20 | 0.37 |
| ▸ | TDP2 | O95551 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7804639 | 0.96 | ECE1 (0.40) | ECE1MUS81EHMT2TOP2AKAT2B | |
| SCHEMBL7810513 | 0.91 | TOP2A (0.43) | ECE1MUS81EHMT2TOP2ATDP2 | |
| SCHEMBL7818082 | 0.89 | TOP2A (0.42) | ECE1MUS81EHMT2TOP2ATDP2 | |
| SCHEMBL7818986 | 0.88 | TOP2A (0.47) | ECE1MUS81EHMT2TOP2AMALT1 | |
| SCHEMBL7810327 | 0.88 | ECE1 (0.43) | ECE1MUS81EHMT2TOP2AKAT2B | |
| SCHEMBL7809049 | 0.88 | EHMT2 (0.39) | EHMT2TOP2AKAT2BMALT1MAPK13 | |
| SCHEMBL7804758 | 0.87 | TOP2A (0.43) | ECE1MUS81EHMT2TOP2ATDP2 | |
| SCHEMBL7810277 | 0.87 | TOP2A (0.42) | ECE1MUS81EHMT2TOP2ATDP2 | |
| Topixantrone SCHEMBL1344518 | 0.85 | TOP2A (0.57) | ECE1MUS81EHMT2TOP2ATDP1 | |
| Topixantrone SCHEMBL29371930 | 0.85 | TOP2A (0.57) | ECE1MUS81EHMT2TOP2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0662076-B1 | 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY | UNIV VERMONT (US) | 2001-04-11 | — | — | EP | claimed |
| EP-0750619-A1 | HETERO-ANNULATED INDAZOLES | BOEHRINGER MANNHEIM ITALIA S.p.A. (IT) | 1997-01-02 | — | — | EP | claimed |
| WO-1995024407-A1 | HETERO-ANNULATED INDAZOLES | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-09-14 | — | — | WO | claimed |
| WO-1994006795-A1 | 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY | THE UNIVERSITY OF VERMONT (US) | 1994-03-31 | — | — | WO | claimed |
| EP-0750619-B1 | HETERO-ANNULATED INDAZOLES | NOVUSPHARMA SPA (IT) | 2001-05-30 | — | — | EP | disclosed |
| EP-0662076-B1 | 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY | UNIV VERMONT (US) | 2001-04-11 | — | — | EP | disclosed |
| US-5604246-A | HAVING POTENCY AGAINST MULTIDRUG RESISTANT TUMORS | BOEHRINGER MANNHEIM ITALIA SPA (IT) | 1997-02-18 | — | — | US | disclosed |
| US-5596097-A | ANTITUMOR AGENTS | THE UNIVERSITY OF VERMONT (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0750619-A1 | HETERO-ANNULATED INDAZOLES | BOEHRINGER MANNHEIM ITALIA S.p.A. (IT) | 1997-01-02 | — | — | EP | disclosed |
| US-5519029-A | ANTITUMOR AGENTS | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1996-05-21 | — | — | US | disclosed |
| WO-1995024407-A1 | HETERO-ANNULATED INDAZOLES | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-09-14 | — | — | WO | disclosed |
| EP-0662076-A1 | 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY | THE UNIVERSITY OF VERMONT (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994006795-A1 | 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY | THE UNIVERSITY OF VERMONT (US) | 1994-03-31 | — | — | WO | disclosed |